Use of a compound of formula or a pharmaceutically acceptable salt thereof: wherein: W, X, Y and Z are each independently selected from CH or N; B and B 1 are independently selected from hydrogen and alkyl or when taken together with the carbon to which they are attached form a carbonyl group; Q is C=O or SO 2; D and D 1 are independently selected from a bond, oxygen and NR c; wherein at least one of D and D 1 is NR c; A is aryl or heteroaryl each substituted with 0-3 occurrences of R 2; R 1 is independently selected from alkyl, acyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, cycloalkylalkyl, aralkyl, and heteroaralkyl; each of which may be optionally substituted with 0-3 occurrences of R d; each R 2 is independently selected from halo, hydroxy, haloalkyl, aryl, heteroaryl, alkyl, -NR c R c', alkyl-NR c R c', -OR a, -C OH, -C OR b,-C NR c R c', cycloalkyl, heterocyclyl, heterocyclylalkyl, cycloalkylalkyl, aralkyl, and heteroaralkyl; each R 3 is independently selected from halo, haloalkyl, alkyl, alkenyl, alkynyl, heterocyclyl and -OR a, or two adjacent R 3 s (when n is 2) taken together with the carbon atoms they are attached to form an optionally substituted heterocyclyl; each R a is independently selected from alkyl, alkoxy, alkylalkoxy, alkylalkoxylalkoxy, alkyl-C OR b, alkyl-C OR b, and haloalkyl; each R b is independently alkyl; each R c and R c' is independently selected from hydrogen, alkyl, alkyl-C OR b and alkenyl; each R d is independently selected from halo, haloalkyl, alkyl, nitro, cyano, and -OR a, or two R d taken together with the carbon atoms to which they are attached form an optionally substituted heterocyclyl; n is 0, 1, or 2; h is 0, 1, 2; and g is 0, 1 or 2; in the manufacture of a medicament for treating a cancer characterized as having an IDH mutation in a subject in need thereof. W, X, Y and Z are each independently selected from CH or N; B and B 1 are independently selected from hydrogen and alkyl or when taken together with the carbon to which they are attached form a carbonyl group; Q is C=O or SO 2; D and D 1 are independently selected from a bond, oxygen and NR c; wherein at least one of D and D 1 is NR c; A is aryl or heteroaryl each substituted with 0-3 occurrences of R 2; R 1 is independently selected from alkyl, acyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, cycloalkylalkyl, aralkyl, and heteroaralkyl; each of which may be optionally substituted with 0-3 occurrences of R d; each R 2 is independently selected from halo, hydroxy, haloalkyl, aryl, heteroaryl, alkyl, -NR c R c', alkyl-NR c R c', -OR a, -C OH, -C OR b,-C NR c R c', cycloalkyl, heterocyclyl, heterocyclylalkyl, cycloalkylalkyl, aralkyl, and heteroaralkyl; each R 3 is independently selected from halo, haloalkyl, alkyl, alkenyl, alkynyl, heterocyclyl and -OR a, or two adjacent R 3 s (when n is 2) taken together with the carbon atoms they are attached to form an optionally substituted heterocyclyl; each R a is independently selected from alkyl, alkoxy, alkylalkoxy, alkylalkoxylalkoxy, alkyl-C OR b, alkyl-C OR b, and haloalkyl; each R b is independently alkyl; each R c and R c' is independently selected from hydrogen, alkyl, alkyl-C OR b and alkenyl; each R d is independently selected from halo, haloalkyl, alkyl, nitro, cyano, and -OR a, or two R d taken together with the carbon atoms to which they are attached form an optionally substituted heterocyclyl; n is 0, 1, or 2; h is 0, 1, 2; and g is 0, 1 or 2; in the manufacture of a medicament for treating a cancer characterized as having an IDH mutation in a subject in need thereof.